orphan neurodegenerative diseases | e-Asfalistiki
Spain: EIB provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases
EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist Venture debt operation…
